Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VANI Vivani Medical, Inc.

Trading 08-19 11:22:39 EDT

1.50

+0.05

+3.51%

High1.53	Low1.45	Vol330.54K
Open1.46	D1 Closing1.45	Amplitude5.52%
Mkt Cap135.39M	Tradable Cap55.34M	Total Shares90.20M
T/O490.26K	T/O Rate0.90%	Tradable Shares36.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VANI","market":"US","secType":"STK","nameCN":"Vivani Medical, Inc.","latestPrice":1.5009,"timestamp":1787152899273,"preClose":1.45,"halted":0,"volume":330543,"delay":0,"changeRate":0.03510344827586203,"floatShares":36870100,"shares":90203400,"eps":-0.353362,"marketStatus":"Trading","change":0.0509,"latestTime":"08-19 11:22:39 EDT","open":1.46,"high":1.53,"low":1.45,"amount":490263.69140099996,"amplitude":0.055172,"askPrice":1.51,"askSize":148,"bidPrice":1.5,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-0.353362,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787169600000},"marketStatusCode":2,"adr":0,"listingDate":1416373200000,"exchange":"NASDAQ","adjPreClose":1.45,"preHourTrading":{"tag":"盘前","latestPrice":1.5,"preClose":1.45,"latestTime":"09:28 EDT","volume":2072,"amount":3036.4018328,"timestamp":1787146080406,"change":0.05,"changeRate":0.034483,"amplitude":0.048276},"postHourTrading":{"tag":"盘后","latestPrice":1.4798,"preClose":1.45,"latestTime":"19:41 EDT","volume":7957,"amount":11776.9676,"timestamp":1787096515805,"change":0.0298,"changeRate":0.020552,"amplitude":0.030138},"volumeRatio":6.058546,"impliedVol":1.4687,"impliedVolPercentile":0.6733},"requestUrl":"/m/hq/s/VANI/tweets","defaultTab":"tweets","newsList":[{"id":"2660498488","title":"Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498488?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:00","pubTimestamp":1787061614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vivani Medical (VANI) and InspireMD (NSPR) with bull...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vivani-medical-vani-and-inspiremd-nspr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vivani-medical-vani-and-inspiremd-nspr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","BK4585","NSPR","XLV","BK4137","HCSG","LU0029874061.USD","BK4198","BK4082","LU0128526141.USD","VANI","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432803","title":"Vivani Medical Posts Investor Deck Outlining NanoPortal Ultra-Long-Acting GLP-1 Implant Strategy for Obesity Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432803","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432803?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:18","pubTimestamp":1786997889,"startTime":"0","endTime":"0","summary":"Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity marketVivani outlined its NanoPortal ultra-long-acting subdermal GLP-1 implant platform targeting once- or twice-yearly dosing for chronic weight management.Lead candidate NPM-139, a semaglutide implant, is in SLIM-1 with top-line data expected in Nov 2026.Phase 2 study design is underway with an anticipated 2027 start for NPM-139.Cash runway is expected to fund the current operating plan through 1H2027, including completion of key milestones.The deck cited $132 billion in 2025 global sales for FDA-approved GLP-1 products, with high discontinuation rates by year 1 and year 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL91gjHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121398","title":"ClearOne Q2 FY26 Net Loss from Continuing Operations Narrows to $919,000; General and Administrative Expense Falls 22% to $849,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121398","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121398?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:42","pubTimestamp":1786740134,"startTime":"0","endTime":"0","summary":"ClearOne Q2 FY26 net loss from continuing operations narrows to $919,000; general and administrative expense falls 22% to $849,000ClearOne posted a GAAP net loss from continuing operations of USD 919,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1WkbCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","VANI","CRGT","BK4082","CLRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144230","title":"Lake Street Remains a Buy on Vivani Medical (VANI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144230?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:15","pubTimestamp":1786713319,"startTime":"0","endTime":"0","summary":"Lake Street analyst Jaeson Schmidt maintained a Buy rating on Vivani Medical today and set a price target of $4.00. According to TipRanks, Schmidt ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-vivani-medical-vani-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-vivani-medical-vani-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659578198","title":"Vivani Medical Q2 EPS USD -0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2659578198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659578198?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:17","pubTimestamp":1786655836,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXPTFR11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167410","title":"Vivani Medical Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167410","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167410?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:31","pubTimestamp":1786653104,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc reports results for the quarter ended June 30 - Earnings SummaryVivani Medical IncVANI.OQreported a quarterly adjusted loss of 7 cents per share for the quarter ended June 30, highe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A26K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167563","title":"Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167563","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167563?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:21","pubTimestamp":1786652499,"startTime":"0","endTime":"0","summary":"Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61193943/vivani-medical-q2-eps-0-07-beats-0-08-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659629201","title":"Press Release: Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659629201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659629201?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"All participants successfully dosed in SLIM-1(TM), the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line dat","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","TM","BK4604","03160","BK4232","VANI","BK4555","BK4585","BK4588","CRGT","BK4099","BK4082","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659625061","title":"Vivani Medical Q2 FY26 Net Loss Narrows 9.86% to $6.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659625061","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659625061?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:04","pubTimestamp":1786651496,"startTime":"0","endTime":"0","summary":"Vivani Medical Q2 FY26 net loss narrows 9.86% to $6.4 millionVivani Medical posted a net loss of USD 6.4 million for the quarter ended June 30, 2026, narrowing from USD 7.1 million.Research and develo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLwxX4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990549","title":"ClearOne Shareholders Back Issuance of 12,500,000 Shares for Cortigent Merger by Written Consent","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990549","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990549?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:09","pubTimestamp":1786442984,"startTime":"0","endTime":"0","summary":"ClearOne shareholders back issuance of 12,500,000 shares for Cortigent merger by written consentClearOne board actions, backed by majority written consent, cleared key steps for a Cortigent acquisitio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL50xVWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRO","BK4020","BK4082","VANI","CRGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657437642","title":"Vivani Medical Inc Expected to Post a Loss of 8 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657437642","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657437642?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:10","pubTimestamp":1786115458,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc <VANI.OQ> expected to post a loss of8cents a share - Earnings PreviewVivani Medical IncVANI.OQVANI.Ois expected to  show no change in quarterly revenue when it reports  results on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636081","title":"Vivani Medical Completes Dosing in SLIM-1 Phase 1 Trial of NPM-139 Semaglutide Implant for Weight Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636081?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:06","pubTimestamp":1786018005,"startTime":"0","endTime":"0","summary":"Vivani Medical completes dosing in SLIM-1 Phase 1 trial of NPM-139 semaglutide implant for weight managementVivani Medical completed enrollment and initial dosing in SLIM-1, a Phase 1 study of NPM-139","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6NqWFb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636644","title":"Vivani Medical Announces Successful Dosing of All Participants in Slim-1, a Phase 1 Trial Evaluating Npm-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636644?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUACH5GFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657957444","title":"ClearOne Cancels Warrants for 437,500 Shares at $5 Exercise Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2657957444","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657957444?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:42","pubTimestamp":1785969772,"startTime":"0","endTime":"0","summary":"ClearOne cancels warrants for 437,500 shares at $5 exercise priceClearOne entered a warrant cancellation agreement on Aug. 4, 2026, cancelling warrants for up to 437,500 common shares.The warrants had","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL608rt2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRO","BK4020","BK4082","VANI","CRGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652023808","title":"Clearone Files Draft Information Statement for Cortigent Merger Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2652023808","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652023808?lang=en_us&edition=fundamental","pubTime":"2026-07-18 05:24","pubTimestamp":1784323463,"startTime":"0","endTime":"0","summary":"ClearOne files draft information statement for Cortigent merger share issuanceClearOne shareholders authorized issuance of 12,500,000 common shares to Vivani in a Cortigent acquisition, triggering a c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL9KYjlb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRO","BK4020","CRGT","BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651426904","title":"Vivani Medical Director, 10% Owner Gregg Williams Reports Purchase of USD 999,999 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2651426904","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651426904?lang=en_us&edition=fundamental","pubTime":"2026-07-16 21:00","pubTimestamp":1784206849,"startTime":"0","endTime":"0","summary":"Vivani Medical director, 10% owner Gregg Williams reports purchase of USD 999,999 common sharesVivani Medical: director, 10% owner Gregg Williams reported buying 793,650 common shares at $1.26 in a pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL1tKThG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivani Medical Director, 10% Owner Gregg Williams Reports Purchase of USD 999,999 Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651489633","title":"Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651489633","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651489633?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:03","pubTimestamp":1784059380,"startTime":"0","endTime":"0","summary":"ALAMEDA, Calif., July  14, 2026  (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3327241/0/en/Vivani-Medical-to-Present-at-the-Emerging-Growth-Conference-on-July-15-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954785","title":"Vivani Medical Signs Deal with Novo Nordisk to Evaluate Npm-139 Semaglutide Implant","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954785","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649954785?lang=en_us&edition=fundamental","pubTime":"2026-07-08 11:12","pubTimestamp":1783480348,"startTime":"0","endTime":"0","summary":"Vivani Medical signs deal with Novo Nordisk to evaluate NPM-139 semaglutide implantVivani signed a new agreement allowing Novo Nordisk to run a non-exclusive internal evaluation of its NPM-139 semaglu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL4s96JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","VANI","IE00BN0W2T93.GBP","BK4585","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","NDAQ","SG9999014005.SGD","LU0314104364.USD","BK4082","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD","LU2210150020.SGD","BK4588","BCDF","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649932346","title":"Vivani Medical Publishes Investor Presentation on Nanoportal Long-acting GLP-1 Implant Pipeline for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2649932346","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649932346?lang=en_us&edition=fundamental","pubTime":"2026-07-08 02:49","pubTimestamp":1783450153,"startTime":"0","endTime":"0","summary":"Vivani Medical publishes investor presentation on NanoPortal long-acting GLP-1 implant pipeline for obesityVivani outlined its NanoPortal miniature drug-implant platform targeting ultra long-acting GL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL8LGTXy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089283258.USD","LU2264538146.SGD","BK4534","LU1791710400.SGD","LU0098860793.USD","LU1720051017.SGD","LU2347655156.SGD","LU2023251221.USD","LU1074936037.SGD","KBWB","LU0210528500.USD","LU0106831901.USD","LU1244550494.USD","LU1989772840.SGD","LU0320765646.SGD","LU1732799900.SGD","BK4516","VANI","LU1732800096.USD","LU1791710582.SGD","LU0158827781.USD","IE00BKVL7J92.USD","LU0390134368.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU2111349929.HKD","LU2133065610.SGD","LU0912757837.SGD","IAI","LU0158827948.USD","LU0795875086.SGD","BK4585","LU0225283273.USD","LU1064131342.USD","LU0314104364.USD","LU2271345857.HKD","LU0267386448.USD","LU0053666078.USD","LU0795875169.SGD","BK4082","LU1244550577.SGD","LU0006306889.USD","LU1548497426.USD","LU2028103732.USD","LU0557290698.USD","BK4581","LU0971096721.USD","LU2357305700.SGD","LU2487616109.SGD","LU2089284900.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649198001","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2649198001","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649198001?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:02","pubTimestamp":1783429368,"startTime":"0","endTime":"0","summary":"Healthcare stocks were rising pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF  1.2% higher and the iShares Biotechnology ETF  up 1.1%.Vivani Medical  said Novo Nordisk  will conduct an internal evaluation of NPM-139, Vivani's semaglutide drug implant intended for chronic weight management, under a new agreement. Shares of Novo Nordisk were up more than 2% premarket.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVO","BK4585","NVOH","XLV","NVOX","VANI","BK4007","IE00BKVL7J92.USD","OZEM","BK4082","BK4581","PPH","XBI","LU0154236417.USD","BK4599","BK4588","THNR","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1093756325.SGD","BK4532","LABU","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivani.com;investors.vivani.com","stockEarnings":[{"period":"1week","weight":0.0432},{"period":"1month","weight":0.0985},{"period":"3month","weight":0.2185},{"period":"6month","weight":0.1154},{"period":"1year","weight":0.1694},{"period":"ytd","weight":0.1789}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.1212},{"period":"1year","weight":0.193},{"period":"ytd","weight":0.1254}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.013761},{"month":2,"riseRate":0.333333,"avgChangeRate":0.262607},{"month":3,"riseRate":0.333333,"avgChangeRate":0.172227},{"month":4,"riseRate":0.416667,"avgChangeRate":0.031848},{"month":5,"riseRate":0.5,"avgChangeRate":0.041822},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.052506},{"month":7,"riseRate":0.5,"avgChangeRate":-0.01797},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.089417},{"month":9,"riseRate":0.636364,"avgChangeRate":-0.039438},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.074632},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.062683},{"month":12,"riseRate":0.333333,"avgChangeRate":0.011596}],"exchange":"NASDAQ","name":"Vivani Medical, Inc.","nameEN":"Vivani Medical, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivani Medical, Inc.(VANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivani Medical, Inc.,VANI,Vivani Medical, Inc.股票,Vivani Medical, Inc.股票老虎,Vivani Medical, Inc.股票老虎国际,Vivani Medical, Inc.行情,Vivani Medical, Inc.股票行情,Vivani Medical, Inc.股价,Vivani Medical, Inc.股市,Vivani Medical, Inc.股票价格,Vivani Medical, Inc.股票交易,Vivani Medical, Inc.股票购买,Vivani Medical, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivani Medical, Inc.(VANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction